Samsung Biologics (207940) will issue 2,270,000 new shares to raise ₩3,000.9bn, the company said in a filing on Friday, after its board approved the rights offering that day with four independent directors present.
The filing splits the proceeds two ways: ₩2,706.2bn to acquire securities in another company and ₩294.8bn for facilities. Existing holders are allotted 0.0392737657 new shares for each share held, against 46,290,951 shares outstanding, with 454,000 shares reserved first for the employee stock ownership association.
The price is provisional. The board set an expected ₩1,322,000 a share, to be fixed on 4 November at a 15% discount to a reference price, with a floor at 60% of that reference.
The ₩3,000.9bn raise equals 66% of the ₩4,557.0bn of revenue Samsung Biologics reported for FY2025.
Shinhan Investment, NH Investment, Korea Investment and KB Securities are joint lead underwriters and will take up shares left unsold. Anyone who sells short between 31 August and 4 November is barred from subscribing.
Subscription runs 9 to 10 November, payment falls on 17 November, and the new shares list on 30 November.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |